Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of GENV HEM

Next Previous
Trial Profile

A clinical trial of GENV HEM

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GENV HEM (Primary)
  • Indications Haemophilia; Haemophilia A
  • Focus Adverse reactions

Most Recent Events

  • 29 Oct 2025 According to a GENV HEM media release, will continue to engage with regulatory authorities as it advances GENV-HEM through IND-enabling studies with a Pre-IND Meeting and IND submission as the next milestones planned for 2026.
  • 07 Oct 2025 According to a GENV HEM media release, an NIH program is validating the science, funding essential toxicology studies, and accelerating progress toward an IND for a one-time gene therapy for hemophilia A, with or without inhibitors, for hemophilia A, including patients with inhibitors.
  • 12 Nov 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top